Source disclosure: January 26, 2026
Veritas In Silico Inc. [130A.T]
TOKYO, Jan 26 (Pulse News Wire) – Veritas In Silico Inc. (130A.T) and Swiss-based SpiroChem AG signed a memorandum of understanding (MOU) to collaborate on researching mRNA-targeting compounds.
The joint research aims to combine SpiroChem’s expertise in macrocycles and peptides with Veritas In Silico's AI-driven mRNA drug discovery platform to develop novel low-molecular-weight compounds targeting RNA.
No upfront payments are expected from the agreement, and the costs associated with the joint research project are included in Veritas In Silico’s budget for the fiscal year ending December 2026. The company does not anticipate significant impacts on future performance due to this collaboration.
AI-translated content. 🟢 Confidence: High See terms • Original filing